Katy Rezvani

Biography
Dr. Katy Rezvani is a pioneering physician scientist whose work has helped define and advance the field of engineered natural killer cell therapy. She has driven the development of cord blood-derived, off-the-shelf NK cell platforms from early discovery through manufacturing and clinical translation, helping establish a new class of cellular immunotherapies and a platform with the potential to expand access, improve scalability and reduce barriers to adoption. Her group provided the first clinical evidence that CAR NK cells can induce meaningful anti-tumor responses with a favorable safety profile, a landmark advance that helped accelerate the field’s growth. She has since led efforts to enhance persistence, in vivo expansion and anti-tumor activity, advancing engineered NK cell therapies for both hematologic malignancies and solid tumors. Beyond these scientific contributions, Dr. Rezvani has built one of the leading translational programs in cellular therapy, integrating discovery science, manufacturing and clinical investigation to accelerate the development of new treatments. Her work has helped move engineered NK cell therapy from promising concept to clinical reality and has played an important role in shaping the future of scalable cell therapy. Through these contributions, Dr. Rezvani has helped broaden the impact of cellular immunotherapy and open new possibilities for patients.

---

Talk
Engineered NK Cells Expanding the Reach of Cellular Immunotherapy
This keynote will highlight the development of engineered NK cell therapies from discovery through clinical translation, including first-in-human CAR NK and TCR-NK cell studies. It will focus on strategies to enhance persistence, scalability and access, and discuss how off-the-shelf platforms are expanding the reach and impact of cellular immunotherapy for cancer and beyond.